Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.59 |
| ▸ | DRD4 | P21917 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13922045 | 0.82 | HTR7 (0.51) | DRD2DRD4DRD3POLBHTR7 | |
| SCHEMBL13922044 | 0.81 | KCNH2 (0.53) | DRD2DRD4DRD3POLBHTR7 | |
| SCHEMBL30741691 | 0.81 | DRD2 (0.56) | DRD2POLB | |
| SCHEMBL4822596 | 0.81 | ALDH1A1 (0.61) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL5783473 | 0.79 | ENPP2 (0.51) | DRD2DRD3POLB | |
| SCHEMBL27225075 | 0.77 | DRD2 (0.62) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL30883414 | 0.77 | DRD2 (0.62) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL18294558 | 0.77 | DRD2 (0.49) | DRD2POLB | |
| SCHEMBL27036802 | 0.77 | DRD2 (0.54) | DRD2 | |
| SCHEMBL4823574 | 0.77 | ALDH1A1 (0.55) | DRD2DRD4DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080027066-A1 | Arylpiperazinyl Compounds | EPIX DELAWARE, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027066-A1 | Arylpiperazinyl Compounds | EPIX DELAWARE, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027066-A1 | Arylpiperazinyl Compounds | EPIX DELAWARE, INC. | 2008-01-31 | — | — | US | disclosed |
| EP-1592425-A4 | NEW ARYLPIPERAZINYL COMPOUNDS | EPIX DELAWARE INC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20070004742-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004742-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004742-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7153858-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1592425-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069794-A9 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDING (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040220192-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004069794-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027066-A1 | Arylpiperazinyl Compounds | HTR5A, HTR1A, HTR2A | DRD2 195/4885DRD4 355/4885DRD3 387/4885 |
| US-20070004742-A1 | Arylpiperazinyl compounds | HTR5A, HTR1A, HTR2A | DRD2 195/4885DRD4 355/4885DRD3 387/4885 |
| US-20040220192-A1 | Arylpiperazinyl compounds | HTR5A, HTR1A, HTR2A | DRD2 195/4885DRD4 355/4885DRD3 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.